The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review
HPV and Gynecologic Cancer
Related content
Pregnancy and ChildbirthReproductive Health
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data
J Clin Oncol.
Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L
doi: 10.1200/JCO.2018.78.0858.
HPV and Gynecologic Cancer
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
Gynecol Oncol.
González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators
doi: 10.1016/j.ygyno.2018.08.036.
HPV and Gynecologic Cancer
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
N Engl J Med.
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS
doi: 10.1056/NEJMoa1708618.
HPV and Gynecologic Cancer
Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies
Br J Clin Pharmacol.
Huo YL, Qiao JM, Gao S
doi: 10.1111/bcp.13498.
HPV and Gynecologic Cancer
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer - is interval cytoreductive surgery still needed?
Am J Obstet Gynecol.
Klein DA, Mann AK, Freeman AH, Liao CI, Kapp DS, Chan JK
doi: 10.1016/j.ajog.2019.07.050.
Overactive BladderUro-Oncology
Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer
Eur Urol Focus.
Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB
doi: 10.1016/j.euf.2018.08.019.
COMMENTED
Uro-Oncology
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.033.
HPV and Gynecologic Cancer
Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma
Gynecol Oncol.
Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G
doi: 10.1016/j.ygyno.2018.08.042.
HPV and Gynecologic Cancer
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
J Clin Oncol.
Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS
doi: 10.1200/JCO.18.01568.